Financial Daily from THE HINDU group of publications
Saturday, Mar 12, 2005

Port Info

Group Sites

Home Page - Pharmaceuticals
Corporate - People

Ranbaxy's R&D chief Rajinder Kumar quits

Our Bureau

New Delhi , March 11

IT'S finally official. Ending months of speculation, Ranbaxy Laboratories Ltd on Friday said that its Research and Development (R&D) head, Dr Rajinder Kumar, has put in his papers and will be returning to the UK.

The company has been reiterating its commitment to R&D and doubled its spend from $13 million (Rs 56.5 crore) in October-December 2003 to $26 million (Rs 113 crore) in the same period in 2004.

Dr Kumar left GlaxoSmithKline Plc to take over as Ranbaxy's R&D head from Dr Rashmi Barbhaiya in July last year. In an official statement, the company has said that it has "reluctantly agreed to his request due to personal circumstances. In due course, he will be invited to join Ranbaxy's R&D Advisory Council''.

Dr Brian Tempest, CEO and Managing Director, said, "We acknowledge the role that Dr Rajinder Kumar has played in institutionalising the R&D regimen, and in particular the clinical processes at Ranbaxy."

Meanwhile, the company has decided to adopt a dual strategy for R&D by separating drug discovery and generics, new drug delivery system (NDDS), and drug development. This it feels would enable greater focus and rigour for success.

While Dr Kasim Mookhtiar will lead the drug discovery team, Dr Vijay Batra will lead the generics, NDDS and drug development research effort of the company. Dr Batra has been working on the anti-malaria molecule as well as the development of atorvastatin (cholesterol busting drug).

The two new R&D heads will be reporting to Dr Tempest, who said that the new structure is designed to bring into sharper focus the unique needs of drug discovery and generics research, while emphasising both equally.

Analysts tracking the sector have expressed concern about the top-level changes in R&D. "While the company has been talking about focusing on R&D, the frequent movement of scientists sends contrary signals," they said. Ranbaxy's stock fell by a marginal 1.23 per cent on the Bombay Stock Exchange to close at Rs 1,069.50.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
HC discharges caveatable interest of 3 Birlas over Priyamvada will

Costlier fuel products push up inflation
Industry grows 8% in Jan
Ranbaxy's R&D chief Rajinder Kumar quits
Emcure launches first 3-in-1 AIDS pill for kids
Sunil Mittal sells personal stock in Bharti Tele
`NPAs in banks rise by Rs 48,784 cr in 7 years'
TRAI slashes global leased line circuit rates by 70 pc — Bandwidth prices set to fall; BPOs, ITeS to benefit
A cruel change in the name of `global practice'
Mutual funds vying to boost IPO collections

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line